Highlights
NASDAQ: BGNE       Beigene Ltd. Ads
Last Price Today's Change   Day's Range   Trading Volume
93.60   -0.27 (0.29%)  92.155 - 95.505  419,676

Overview

 
Avg Volume (4 weeks):390,157
4 Weeks Range:77.54 - 98.89
4 Weeks Price Volatility (%):
75.22%
52 Weeks Range:27.89 - 118.95
52 Weeks Price Volatility (%):
72.16%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

  Be the first to like this.
 


 

4784  2647  513  587 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 266.51+0.85 
 XLF 27.81+0.12 
 SIRI 5.37-0.29 
 BAC 29.04+0.31 
 GE 17.82+0.18 
 EEM 46.17+0.10 
 TEVA 18.61+1.31 
 ORCL 48.30-1.89 
 QQQ 157.65+1.77 
 IWM 152.24+2.14 
Partners & Brokers